Freed From Pfizer, Capsugel May Find More Market Opportunities
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.
You may also be interested in...
Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says
Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.
Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says
Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.
Sales & Earnings In Brief
NBTY CEO suggests growth trends